サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463157

抗肥満薬市場、シェア、規模、動向、産業分析レポート：作用機序別、製品別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 117 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
抗肥満薬市場、シェア、規模、動向、産業分析レポート：作用機序別、製品別、流通チャネル別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の抗肥満薬市場規模は2032年までに734億7,085万米ドルに達する見込みです。同レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

抗肥満薬は、健康的な体重を達成・維持するために、食事の調整や身体活動のような生活習慣の改善だけでは不十分であることが判明した場合に特に、個人の余剰体重を制御・減少させることを支援するために作られた医薬品物質です。これらの医薬品は、代謝の調節、脂肪吸収の抑制、食欲の抑制など、多様なメカニズムで作用します。ヘルスケア提供者は通常、肥満度指数（BMI）が高い患者や2型糖尿病のような肥満に関連した健康問題を抱える患者など、特定の基準を満たす患者に処方します。

抗肥満薬市場は、体重管理に関する社会的認識の変化、肥満率の世界の上昇、医薬品研究の進歩などの要因に影響され、時間の経過とともに様々な成長を遂げてきました。最近では、肥満に関連する健康被害に対する意識の高まりや、より効率的で安全な治療オプションに対する需要に後押しされ、この市場に対する関心が再び高まっています。同市場では、減量結果の改善と副作用の最小化を目的とした、併用療法を含む新規薬剤のイントロダクションが示されています。さらに、ヘルスケアプロバイダーは、生活習慣の改善、行動介入、薬物治療を含む包括的な肥満管理アプローチを重視するようになってきています。

さらに、世界的に肥満の有病率が上昇し、関連する健康リスクに対する認識が高まる中、効果的な治療オプションに対する需要が高まっています。医薬品開発技術の進歩は、有効性と安全性のプロファイルを改善した新規医薬品の導入機会を提供しています。さらに、体重管理に対する社会の考え方の変化や、予防ヘルスケアの重視の高まりは、市場の成長を促進すると予想されます。さらに、デジタルヘルス・ソリューションと個別化医療アプローチの統合は、個々の患者のニーズに合わせて治療をカスタマイズする道を提供し、それによって市場範囲を拡大します。さらに、製薬企業とヘルスケアプロバイダーとの戦略的提携や研究開発への投資の増加は、このダイナミックで進化する市場情勢においてさらなるビジネスチャンスをもたらすと考えられます。

抗肥満薬市場レポートハイライト

2023年、末梢作用型抗肥満薬セグメントは、栄養吸収を改善し空腹感を軽減するメカニズムの能力により、最大の収益シェアを占めました。

2023年には、小売薬局セグメントが大きな収益シェアを占めるようになった。これらの店舗は、消費者に薬への便利なアクセスを提供し、一般的に地域内のアクセスしやすい場所に位置しています。

2023年、北米地域は、肥満の高い有病率や政府の支援政策などの様々な要因により、最大の市場シェアを占めました。さらに、製薬大手の合併、買収、提携などの戦略的な動きは、競合情勢の形成に極めて重要な役割を果たしています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の抗肥満薬市場の洞察

  • 抗肥満薬市場- 流通チャネルのスナップショット
  • 抗肥満薬市場力学
    • 促進要因と機会
      • 肥満の増加
      • 小児肥満および病的肥満の発生の増加
    • 抑制要因と課題
      • 長期的な有効性に関するデータの欠如
  • PESTEL分析
  • 抗肥満薬市場の流通チャネル動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 製品別の世界市場

  • 主な調査結果
  • イントロダクション
  • 未公認
  • 承認

第6章 作用機序別の世界市場

  • 主な調査結果
  • イントロダクション
  • 中枢作用薬
  • 末梢作用薬

第7章 流通チャネル別の世界市場

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第8章 地域別の世界市場

  • 主な調査結果
  • イントロダクション
    • 抗肥満薬市場評価、地域別、2019-2032年
  • 抗肥満薬市場-北米
    • 北米：抗肥満薬市場、製品別、2019年～2032年
    • 北米：抗肥満薬市場、流通チャネル別、2019年～2032年
    • 北米：抗肥満薬市場、作用機序別、2019年～2032年
    • 抗肥満薬市場-米国
    • 抗肥満薬市場- カナダ
  • 抗肥満薬市場- 欧州
    • 欧州：抗肥満薬市場、製品別、2019年～2032年
    • 欧州：抗肥満薬市場、流通チャネル別、2019年～2032年
    • 欧州：抗肥満薬市場、作用機序別、2019年～2032年
    • 抗肥満薬市場- 英国
    • 抗肥満薬市場- フランス
    • 抗肥満薬市場- ドイツ
    • 抗肥満薬市場- イタリア
    • 抗肥満薬市場- スペイン
    • 抗肥満薬市場- オランダ
    • 抗肥満薬市場- ロシア
  • 抗肥満薬市場- アジア太平洋地域
    • アジア太平洋地域：抗肥満薬市場、製品別、2019年～2032年
    • アジア太平洋地域：抗肥満薬市場、流通チャネル別、2019年～2032年
    • アジア太平洋地域：抗肥満薬市場、作用機序別、2019年～2032年
    • 抗肥満薬市場- 中国
    • 抗肥満薬市場- インド
    • 抗肥満薬市場- マレーシア
    • 抗肥満薬市場- 日本
    • 抗肥満薬市場- インドネシア
    • 抗肥満薬市場- 韓国
  • 抗肥満薬市場-中東・アフリカ
    • 中東およびアフリカ：抗肥満薬市場、製品別、2019-2032年
    • 中東およびアフリカ：抗肥満薬市場、流通チャネル別、2019-2032年
    • 中東およびアフリカ：抗肥満薬市場、作用機序別、2019-2032年
    • 抗肥満薬市場- サウジアラビア
    • 抗肥満薬市場-UAE
    • 抗肥満薬市場- イスラエル
    • 抗肥満薬市場- 南アフリカ
  • 抗肥満薬市場-ラテンアメリカ
    • ラテンアメリカ：抗肥満薬市場、製品別、2019年～2032年
    • ラテンアメリカ：抗肥満薬市場、流通チャネル別、2019年～2032年
    • ラテンアメリカ：抗肥満薬市場、作用機序別、2019年～2032年
    • 抗肥満薬市場- メキシコ
    • 抗肥満薬市場- ブラジル
    • 抗肥満薬市場- アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/公開

第10章 企業プロファイル

  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals
  • Gelesis
  • GlaxoSmithKline plc
  • Kintai Therapeutics
  • Novartis AG
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals, Inc
  • VIVUS LLC
図表

List of Tables

  • Table 1 Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 2 Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 3 Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 4 Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 6 North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 7 North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 8 U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 9 U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 10 U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 12 Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 13 Canada: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 15 Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 16 Europe: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 18 UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 19 UK: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 20 France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 21 France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 22 France: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 24 Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 25 Germany: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 27 Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 28 Italy: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 30 Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 31 Spain: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 32 Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 33 Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 34 Netherlands: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 36 Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 37 Russia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 42 China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 43 China: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 44 India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 45 India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 46 India: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 48 Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 49 Malaysia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 51 Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 52 Japan: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 54 Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 55 Indonesia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 56 South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 57 South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 58 South Korea: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 65 UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 66 UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 67 UAE: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 68 Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 69 Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 70 Israel: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 71 South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 72 South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 73 South Africa: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 75 Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 76 Latin America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 77 Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 78 Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 79 Mexico: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 80 Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 81 Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 82 Brazil: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 83 Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 84 Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 85 Argentina: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Anti-Obesity Medication Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Mechanism of Action
  • Figure 7. Global Anti-Obesity Medication Market, by Mechanism of Action, 2022 & 2032 (USD Million)
  • Figure 8. Market by Product
  • Figure 9. Global Anti-Obesity Medication Market, by Product, 2022 & 2032 (USD Million)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Anti-Obesity Medication Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 12. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Anti-Obesity Medication Market
目次
Product Code: PM4814

The global anti-obesity medication market size is expected to reach USD 73,470.85 million by 2032, according to a new study by Polaris Market Research. The report "Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Anti-obesity medications are pharmaceutical substances crafted to aid individuals in controlling and reducing their surplus body weight, particularly when lifestyle modifications like dietary adjustments and physical activity alone prove insufficient for attaining and sustaining a healthy weight. These medications can operate through diverse mechanisms, such as modifying metabolism, inhibiting fat absorption, and suppressing appetite. Healthcare providers typically prescribe them to patients meeting specific criteria, such as those with elevated body mass index (BMI) or obesity-related health issues like type 2 diabetes.

The market for anti-obesity medication has experienced variable growth over time, influenced by factors such as shifting societal perceptions regarding weight management, the global escalation in obesity rates, and advancements in pharmaceutical research. In recent times, there has been a resurgence of interest in this market, spurred by heightened awareness of the health hazards linked to obesity and the demand for more efficient and safe treatment options. The market has witnessed the introduction of novel medications, including combination therapies, aimed at improving weight loss outcomes and minimizing adverse effects. Furthermore, healthcare providers are increasingly emphasizing a comprehensive approach to managing obesity, encompassing lifestyle modifications, behavioral interventions, and pharmaceutical treatments.

Additionally, with a rising prevalence of obesity worldwide and an increasing awareness of associated health risks, there is a growing demand for effective treatment options. Advancements in drug development technologies present opportunities for the introduction of novel medications with improved efficacy and safety profiles. Additionally, shifting societal attitudes towards weight management and the growing emphasis on preventive healthcare are expected to drive market growth. Moreover, the integration of digital health solutions and personalized medicine approaches offers avenues for tailoring treatments to individual patient needs, thereby expanding market reach. Furthermore, strategic collaborations between pharmaceutical companies and healthcare providers, as well as increased investment in research and development, are poised to unlock further opportunities in this dynamic and evolving market landscape.

Anti-Obesity Medication Market Report Highlights

In 2023, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share, due to the mechanism's ability to improve nutrient absorption and reduce feelings of hunger.

In 2023, the retail pharmacies segment emerged as the significant revenue share. These outlets provide convenient access to medications for consumers and are commonly located in easily accessible areas within communities.

In 2023, the North American region dominated the largest market share due to various factors, such as the high prevalence of obesity and supportive government policies. Additionally, strategic maneuvers like mergers, acquisitions, and partnerships among pharmaceutical giants play a pivotal role in shaping the competitive landscape.

The global key market players include Boehringer Ingelheim International GmbH, Currax Pharmaceuticals, Gelesis, GlaxoSmithKline plc, Kintai Therapeutics, Novartis AG, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., VIVUS LLC.

Polaris Market Research has segmented the Anti-Obesity Medication market report based on mechanism of action, product, distribution channel, and region:

Anti-Obesity Medication, Mechanism of Action Outlook (Revenue - USD Million, 2019 - 2032)

  • Centrally Acting Drugs
  • Peripherally Acting Drugs

Anti-Obesity Medication, Product Outlook (Revenue - USD Million, 2019 - 2032)

  • Off Label
  • Semaglutide (Wegovy)
  • Topiramate (Xenical Alli)
  • Dulaglutide (Trulicity)
  • Liraglutide (Semaglutide (Wegovy))
  • Others
  • Approved
  • Liraglutide (Orlistat)
  • Bupropion-naltrexone (Contrave)
  • Orlistat
  • Alli
  • Xenical
  • Setmelanotide (Imcivree)
  • Tirzepatide (Zepbound)
  • Phentermine-topiramate (Qsymia)
  • Semaglutide (Wegovy

Anti-Obesity Medication, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Anti-Obesity Medication, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Anti-Obesity Medication Market Insights

  • 4.1. Anti-Obesity Medication Market - Distribution Channel Snapshot
  • 4.2. Anti-Obesity Medication Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The increasing incidence of obesity
      • 4.2.1.2. A rise in the occurrence of childhood obesity and morbid obesity
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of long-term effectiveness data
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Anti-Obesity Medication Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Anti-Obesity Medication Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • 5.3. Off Label
    • 5.3.1. Global Anti-Obesity Medication Market, by Off Label, by Region, 2019-2032 (USD Million)
    • 5.3.2. Semaglutide (Wegovy)
      • 5.3.2.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)
    • 5.3.3. Topiramate (Xenical Alli)
      • 5.3.3.1. Global Anti-Obesity Medication Market, by Topiramate (Xenical Alli), by Region, 2019-2032 (USD Million)
    • 5.3.4. Dulaglutide (Trulicity)
      • 5.3.4.1. Global Anti-Obesity Medication Market, by Dulaglutide (Trulicity), by Region, 2019-2032 (USD Million)
    • 5.3.5. Liraglutide (Semaglutide (Wegovy))
      • 5.3.5.1. Global Anti-Obesity Medication Market, by Liraglutide (Semaglutide (Wegovy)), by Region, 2019-2032 (USD Million)
    • 5.3.6. Others
      • 5.3.6.1. Global Anti-Obesity Medication Market, by Others, by Region, 2019-2032 (USD Million)
  • 5.4. Approved
    • 5.4.1. Global Anti-Obesity Medication Market, by Approved, by Region, 2019-2032 (USD Million)
    • 5.4.2. Liraglutide (Orlistat)
      • 5.4.2.1. Global Anti-Obesity Medication Market, by Liraglutide (Orlistat), by Region, 2019-2032 (USD Million)
    • 5.4.3. Bupropion-naltrexone (Contrave)
      • 5.4.3.1. Global Anti-Obesity Medication Market, by Bupropion-naltrexone (Contrave), by Region, 2019-2032 (USD Million)
    • 5.4.4. Orlistat
      • 5.4.4.1. Global Anti-Obesity Medication Market, by Orlistat, by Region, 2019-2032 (USD Million)
      • 5.4.4.2. Alli
      • 5.4.4.2.1. Global Anti-Obesity Medication Market, by Alli, by Region, 2019-2032 (USD Million)
      • 5.4.4.3. Xenical
      • 5.4.4.3.1. Global Anti-Obesity Medication Market, by Xenical, by Region, 2019-2032 (USD Million)
    • 5.4.5. Setmelanotide (Imcivree)
      • 5.4.5.1. Global Anti-Obesity Medication Market, by Setmelanotide (Imcivree), by Region, 2019-2032 (USD Million)
    • 5.4.6. Tirzepatide (Zepbound)
      • 5.4.6.1. Global Anti-Obesity Medication Market, by Tirzepatide (Zepbound), by Region, 2019-2032 (USD Million)
    • 5.4.7. Phentermine-topiramate (Qsymia)
      • 5.4.7.1. Global Anti-Obesity Medication Market, by Phentermine-topiramate (Qsymia), by Region, 2019-2032 (USD Million)
    • 5.4.8. Semaglutide (Wegovy)
      • 5.4.8.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)

6. Global Anti-Obesity Medication Market, by Mechanism of Action

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 6.3. Centrally Acting Drugs
    • 6.3.1. Global Anti-Obesity Medication Market, by Centrally Acting Drugs, by Region, 2019-2032 (USD Million)
  • 6.4. Peripherally Acting Drugs
    • 6.4.1. Global Anti-Obesity Medication Market, by Peripherally Acting Drugs, by Region, 2019-2032 (USD Million)

7. Global Anti-Obesity Medication Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Anti-Obesity Medication Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Anti-Obesity Medication Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Anti-Obesity Medication Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Anti-Obesity Medication Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Anti-Obesity Medication Market - North America
    • 8.3.1. North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.3.2. North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.3. North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.3.4. Anti-Obesity Medication Market - U.S.
      • 8.3.4.1. U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.3.5. Anti-Obesity Medication Market - Canada
      • 8.3.5.1. Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.4. Anti-Obesity Medication Market - Europe
    • 8.4.1. Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.3. Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.4. Anti-Obesity Medication Market - UK
      • 8.4.4.1. UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.5. Anti-Obesity Medication Market - France
      • 8.4.5.1. France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.5.3. France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.6. Anti-Obesity Medication Market - Germany
      • 8.4.6.1. Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.7. Anti-Obesity Medication Market - Italy
      • 8.4.7.1. Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.8. Anti-Obesity Medication Market - Spain
      • 8.4.8.1. Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.9. Anti-Obesity Medication Market - Netherlands
      • 8.4.9.1. Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.10. Anti-Obesity Medication Market - Russia
      • 8.4.10.1. Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.5. Anti-Obesity Medication Market - Asia Pacific
    • 8.5.1. Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.4. Anti-Obesity Medication Market - China
      • 8.5.4.1. China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.4.3. China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.5. Anti-Obesity Medication Market - India
      • 8.5.5.1. India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.5.3. India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.6. Anti-Obesity Medication Market - Malaysia
      • 8.5.6.1. Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.7. Anti-Obesity Medication Market - Japan
      • 8.5.7.1. Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.8. Anti-Obesity Medication Market - Indonesia
      • 8.5.8.1. Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.9. Anti-Obesity Medication Market - South Korea
      • 8.5.9.1. South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.6. Anti-Obesity Medication Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.4. Anti-Obesity Medication Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.5. Anti-Obesity Medication Market - UAE
      • 8.6.5.1. UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.6. Anti-Obesity Medication Market - Israel
      • 8.6.6.1. Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.7. Anti-Obesity Medication Market - South Africa
      • 8.6.7.1. South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.7. Anti-Obesity Medication Market - Latin America
    • 8.7.1. Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.4. Anti-Obesity Medication Market - Mexico
      • 8.7.4.1. Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.5. Anti-Obesity Medication Market - Brazil
      • 8.7.5.1. Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.6. Anti-Obesity Medication Market - Argentina
      • 8.7.6.1. Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Boehringer Ingelheim International GmbH
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Currax Pharmaceuticals
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Gelesis
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. GlaxoSmithKline plc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Kintai Therapeutics
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novo Nordisk A/S
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Rhythm Pharmaceuticals, Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. VIVUS LLC
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development